Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone
Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone
复制标题
DOI:
10.1111/j.0013-9580.2004.30503.x
复制
发表时间:
2004-03-01
期刊:
影响因子:
5.6
通讯作者:
Shinnar, S
中科院分区:
文献类型:
--
作者:
Kivity, S;Lerman, T;Shinnar, S
Purpose: To evaluate the outcome of children with cryptogenic infantile spasms treated with high-close synthetic adrenocorticotropic hormone (ACTH) and the relation between early treatment, within 1 month of onset, and outcome.Methods: We assessed the long-term cognitive and seizure outcomes of 37 patients with cryptogenic infantile spasms (onset, a-e 3 to 9 months) receiving standardized treatment regimen of hi-h-dose tetracosactide depot, 1 mg IM every 48 h for 2 weeks. with a subsequent 8- to 10-week slow taper and followed by oral prednisone. 10 mg/day for a month, with a subsequent slow taper for 5 Months Or until the infant reached the age of 1 year, whichever came later. Development was assessed before treatment. Seizure outcomes were followed up prospectively. Cognitive outcomes were determined after 6 to 2 1 years and analyzed in relation to treatment lag and pretreatment regression.Results: Twenty-two infants were treated within 1 month of onset of infantile spasms, and 15 after 1 to 6.5 months. Normal cognitive outcome was found in all 22 (100%) patients of the early-treatment group, and in 40% of the late-treatment group. Normal cognitive outcome was found in all 25 (100%) patients who had no or only mild mental deterioration at presentation, including four in the late-treatment group but in only three of the 12 patients who had had marked or severe deterioration before treatment.Conclusions: Early treatment of cryptogenic infantile spasms with a high-dose ACTH protocol is associated with favorable long-term cognitive outcomes. Once major developmental regression lasts for a month or more. the prognosis for normal cognitive outcome is poor. Further studies are needed oil the optimal treatment regimen for this disorder.